title: Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
abstract: This phase III, randomized, open-label, multicenter study (NCT01027845) conducted in Japan assessed the immunogenicity, safety, and reactogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, given intramuscularly) co-administered with diphtheria-tetanus-acellular pertussis vaccine (DTPa, given subcutaneously). Infants (N=360 ) were randomized (2:1) to receive either PHiD-CV and DTPa (PHiD-CV group) or DTPa alone (control group) as 3-dose primary vaccination (3-4-5 months of age) and booster vaccination (17-19 months of age). Immune responses were measured before and one month after primary/booster vaccination and adverse events (AEs) were recorded. Post-primary immune responses were non-inferior to those in pivotal/efficacy European or Latin American pneumococcal protein D-conjugate vaccine studies. For each PHiD-CV serotype, at least 92.6% of infants post-primary vaccination and at least 97.7% of children post-booster had pneumococcal antibody concentrations ≥0.2 μg/ml, and at least 95.4% post-primary and at least 98.1% post-booster had opsonophagocytic activity (OPA) titers ≥8 . Geometric mean antibody concentrations and OPA titers (except OPA titer for 6B) were higher post-booster than post-priming for each serotype. All PHiD-CV-vaccinated children had anti-protein D antibody concentrations ≥100 EL.U/ml one month post-primary/booster vaccination and all were seroprotected/seropositive against each DTPa antigen. Redness and irritability were the most common solicited AEs in both groups. Incidences of unsolicited AEs were comparable between groups. Serious AEs were reported for 47 children (28 in PHiD-CV group); none were assessed as vaccine-related. In conclusion, PHiD-CV induced robust immune responses and was well tolerated when co-administered with DTPa in a 3-dose priming plus booster regimen to Japanese children.
authors.affiliation: a Department of Infectious Diseases ; School of Medicine; Keio University ; Shinjuku-ku , Tokyo , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iwata
authors.forename: Naohisa
authors.initials: N
authors.lastname: Kawamura
authors.forename: Haruo
authors.initials: H
authors.lastname: Kuroki
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Tokoeda
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Miyazu
authors.forename: Asayuki
authors.initials: A
authors.lastname: Iwai
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Oishi
authors.forename: Tomohide
authors.initials: T
authors.lastname: Sato
authors.forename: Akari
authors.initials: A
authors.lastname: Suyama
authors.forename: Nancy
authors.initials: N
authors.lastname: François
authors.forename: Fakrudeen
authors.initials: F
authors.lastname: Shafi
authors.forename: Javier
authors.initials: J
authors.lastname: Ruiz-Guiñazú
authors.forename: Dorota
authors.initials: D
authors.lastname: Borys
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D005260:Female; D006193:Haemophilus influenzae / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: C586648:10-valent pneumococcal conjugate vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; C547294:PHiD-CV vaccine; D022242:Pneumococcal Vaccines
keywords: 7vCRM, 7-valent pneumococcal CRM-conjugate vaccine; AE, adverse event; AOM, acute otitis media; ATP, according-to-protocol; CAP, community-acquired pneumonia; CI, confidence interval; COMPAS, Clinical Otitis Media and PneumoniA Study; DTPa, diphtheria-tetanus-acellular pertussis; ELISA, enzyme-linked immunosorbent assay; GMC, geometric mean concentration; GMT, geometric mean titer; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; IPD, invasive pneumococcal disease; Japan; NTHi, nontypeable Haemophilus influenzae; OPA, opsonophagocytic activity; PCV, pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; POET, Pneumococcal Otitis Efficacy Trial; SAE, serious adverse event; SAS, Statistical Analysis System; SDD, SAS Drug and Development; WHO, World Health Organization; children; co-administration; immunogenicity; pneumococcal conjugate vaccine; safety
references.citation: Clin Diagn Lab Immunol. 2001 Mar;8(2):266-72
references.pmid: 11238206
references.citation: J Antimicrob Chemother. 2005 Oct;56(4):756-60
references.pmid: 16131518
references.citation: Lancet. 2006 Mar 4;367(9512):740-8
references.pmid: 16517274
references.citation: Clin Vaccine Immunol. 2006 Mar;13(3):356-60
references.pmid: 16522777
references.citation: Vaccine. 2007 Mar 22;25(13):2518-27
references.pmid: 17034907
references.citation: Vaccine. 2007 Mar 1;25(11):1962-8
references.pmid: 17258357
references.citation: J Clin Microbiol. 2008 Nov;46(11):3808-10
references.pmid: 18832131
references.citation: Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18
references.pmid: 19325447
references.citation: Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S66-76
references.pmid: 19325449
references.citation: Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108
references.pmid: 19325452
references.citation: Epidemiol Infect. 2010 Jan;138(1):61-8
references.pmid: 19538821
references.citation: Vaccine. 2009 Sep 25;27(42):5748-54
references.pmid: 19666154
references.citation: Lancet. 2009 Sep 12;374(9693):893-902
references.pmid: 19748398
references.citation: Expert Rev Vaccines. 2009 Nov;8(11):1479-500
references.pmid: 19863240
references.citation: Clin Vaccine Immunol. 2010 Jan;17(1):134-42
references.pmid: 19889940
references.citation: BMC Pediatr. 2010 Feb 02;10:4
references.pmid: 20122261
references.citation: J Infect Chemother. 2011 Jun;17(3):334-40
references.pmid: 21161561
references.citation: MMWR Recomm Rep. 2011 Jan 28;60(2):1-64
references.pmid: 21293327
references.citation: Lancet. 2011 Dec 3;378(9807):1962-73
references.pmid: 21492929
references.citation: J Infect Chemother. 2011 Dec;17(6):799-802
references.pmid: 21701961
references.citation: Kansenshogaku Zasshi. 2011 May;85(3):227-37
references.pmid: 21706841
references.citation: Epidemiol Infect. 2012 Jun;140(6):1111-21
references.pmid: 21875450
references.citation: Hum Vaccin. 2011 Oct;7(10):1012-8
references.pmid: 21941097
references.citation: Clin Vaccine Immunol. 2011 Dec;18(12):2161-7
references.pmid: 21994351
references.citation: Int J Otolaryngol. 2012;2012:312935
references.pmid: 22701486
references.citation: Lancet. 2013 Jan 19;381(9862):214-22
references.pmid: 23158882
references.citation: Jpn J Antibiot. 2012 Oct;65(5):305-21
references.pmid: 23383433
references.citation: Microb Drug Resist. 2013 Aug;19(4):308-15
references.pmid: 23480525
references.citation: Pediatr Infect Dis J. 2013 Sep;32(9):984-9
references.pmid: 23538524
references.citation: Emerg Infect Dis. 2013 Apr;19(4):589-97
references.pmid: 23628462
references.citation: J Infect Chemother. 2013 Jun;19(3):412-25
references.pmid: 23657429
references.citation: Jpn J Infect Dis. 2013;66(3):235-7
references.pmid: 23698486
references.citation: Pediatr Infect Dis J. 2013 Dec;32(12):1394-6
references.pmid: 23804122
references.citation: PLoS One. 2013 Jul 02;8(7):e68711
references.pmid: 23844235
references.citation: JAMA. 2013 Sep 4;310(9):930-7
references.pmid: 24002279
references.citation: PLoS One. 2013 Sep 23;8(9):e74906
references.pmid: 24086394
references.citation: Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S119-29
references.pmid: 24336054
references.citation: Vaccine. 2014 Mar 14;32(13):1501-6
references.pmid: 24486346
references.citation: Lancet Respir Med. 2014 Jun;2(6):464-71
references.pmid: 24726406
references.citation: PLoS Med. 2014 Jun 03;11(6):e1001657
references.pmid: 24892763
references.citation: PLoS One. 2017 Jun 8;12(6):e0179222
references.pmid: 28594913
references.citation: Acta Paediatr Jpn. 1995 Oct;37(5):562-74
references.pmid: 8533580
references.citation: Clin Diagn Lab Immunol. 1997 Jul;4(4):415-22
references.pmid: 9220157